Premium
Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature
Author(s) -
MeyerWittkopf M.,
Barth H.,
Emons G.,
Schmidt S.
Publication year - 2001
Publication title -
ultrasound in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.202
H-Index - 141
eISSN - 1469-0705
pISSN - 0960-7692
DOI - 10.1046/j.1469-0705.2001.00373.x
Subject(s) - medicine , cardiotoxicity , anthracycline , doxorubicin , chemotherapy , breast cancer , fetus , pregnancy , cancer , obstetrics , cardiology , gynecology , biology , genetics
Abstract Cardiotoxicity is a recognized complication of anthracycline drugs given as part of chemotherapy; however, the pre‐ and postnatal cardiac effects of in utero exposure are not well documented. In this report we present a case of gestational breast cancer with initiation of four cycles of doxorubicin/cyclophosphamide chemotherapy after modified radical mastectomy and axilla dissection during the early second trimester. Serial echocardiographic measurements of the ventricular shortening fraction and biometry of the ventricular cavities were performed. Allowing for the individual variability of these values in the fetus no myocardial dysfunction was observed. The literature was reviewed in an attempt to delineate the possible role of prenatal echocardiography in the diagnosis of doxorubicin‐induced cardiotoxicity in the fetus. Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology